Mesoblast (ASX:MSB) Shares Rally Meets Persistent Cash Burn

The market has Mesoblast trading around A$2.41 after a choppy week that left the stock down about 4% over seven days but still up double digits over one and three months. That price action suggests investors are torn between excitement over the story and concern about the cost of pursuing that growth.

The main takeaway from this earnings release is straightforward. Mesoblast reported its first full commercial year of RYONCIL revenue at US$115 million, yet still posted a net loss of US$57.5 million and ongoing cash burn. The appeal of a rapid commercial ramp is meeting the reality of margin pressure and a squeeze on profitability.

Love Mesoblast's commercial traction with RYONCIL but concerned about the ongoing losses and cash burn? Check out our 12 resilient stocks with low risk scores for stocks that pair growth stories with stronger balance sheets and lower risk profiles.

FY 2026 Earnings Summary

• Total Revenue FY 2026 vs FY 2025 (trailing 12 months): US$120.25 million vs. US$17.20 million (very large increase, reflecting early commercial scale up for RYONCIL)
• Net Income FY 2026 vs FY 2025 (trailing 12 months): loss of US$57.5 million vs. loss of US$102.14 million (loss narrowed by 44%)
• Basic EPS FY 2026 vs FY 2025 (trailing 12 months): loss of US$0.0444 per share vs. loss of US$0.0846 per share (loss per share almost halved)
• Gross Profit FY 2026 (excluding amortization): approximately US$110 million on net revenue of US$115 million (indicating very high gross profitability on the current product mix)

Prefer clean charts over scrolling through another page of earnings tables and cash flow figures? See Mesoblast's overall financial picture in a visual format, including how the balance sheet lines up against the current RYONCIL ramp, in our company report for Mesoblast.

Mesoblast bull case hinges on RYONCIL proof points

The bullish story on Mesoblast is that RYONCIL can fund a broader cell therapy platform while de risking the pipeline. FY26 gives some support to that. Net revenue of US$115 million with gross profit of about US$110 million shows the product can throw off cash at the unit level. Management has more than 50 U.S. centers onboarded and reports payer coverage for over 98% of lives, plus nationwide Medicaid and a J code, which addresses early concerns about reimbursement friction. Phase 3 treatment completion in chronic low back pain and a BLA number for the LVAD bleeding indication show the second generation assets are progressing along the regulatory path. However, the company still reported a net loss of US$57.5 million, so the model of self funding growth is not yet achieved.

Bear case focuses on cash burn and concentration risk

The bearish view is that Mesoblast is over reliant on a narrow pediatric indication while burning cash and leaning on debt. FY26 does not fully dispel that. RYONCIL revenue is still concentrated in pediatric steroid refractory acute GvHD, and although adult GvHD and Duchenne programs are moving, the adult trial is only part way through enrollment with key analysis not expected until Q4 2027. The company reported a net loss of US$57.5 million and net cash usage of US$43.8 million, even after a very high gross margin year. The new US$50 million facility and total US$125 million credit line reduce immediate dilution but add 8% interest obligations. H2 cash burn improved to US$13.4 million, which partially addresses liquidity worries, but does not yet remove the risk that further funding could be needed.

Compare Mesoblast's rapid RYONCIL ramp, high gross profitability and narrowing loss with what institutional analysts are signalling on the stock. See the consensus price target analysis for Mesoblast to check whether the latest targets line up with the current A$2.41 share price.

Stay Ahead With Mesoblast Insights

If Mesoblast's rapid RYONCIL rollout, high gross profitability and ongoing cash burn have your attention, register for free with Simply Wall St and add it to a Watchlist to track its share price against fair value and watch how the story develops. Once you own Mesoblast or other stocks, use the Portfolio Command Center to cut through noise and focus on the key updates that matter for your holdings. For the longer term, tap into crowd insight through the Community and see how other investors are thinking about risks, funding needs and new catalysts. This combination can help you surface hidden catalysts and potential red flags early so you stay a step ahead of the market.

Seeking Alternatives Beyond Mesoblast?

Market momentum can shift fast, and the most interesting ideas often move from under the radar to fully priced before you notice. Scan these fresh stock themes now and consider getting in early.

• Spot cash rich companies that still show room for a breakout by scanning our curated 13 high quality undervalued stocks while these opportunities remain under the radar for now.
• Consider the next wave of automation momentum by zeroing in on businesses in the 38 robotics and automation stocks before the crowd fully catches on to their potential.
• Track the AI infrastructure build out by following companies in the 55 AI infrastructure stocks while valuations and expectations are still settling.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com